Other preclinical studies have supported the synergistic interaction between venetoclax and PI3K inhibitors in inducing BAX-dependent mitochondrial apoptosis of AML cells [44]; interestingly, this drug combination was also very active in killing CD34+/CD38−/CD123+ leukemic stem cells [44]. Here, BAX is linked to acute myeloid leukemia.